Wainwright CE Elborn JS Ramsey BW Marigowda G Huang X Cipolli M et al.

Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.

N Engl J Med. 2015; 373: 220-231View in Article Scopus (740) PubMed Crossref Google ScholarRatjen F Hug C Marigowda G Tian S Huang X Stanojevic S et al.

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

The Lancet Respir Med. 2017; 5: 557-567View in Article Scopus (155) PubMed Abstract Full Text Full Text PDF Google ScholarRamsey BW Davies J McElvaney NG Tullis E Bell SC Drevinek P et al.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

N Engl J Med. 2011; 365: 1663-1672View in Article Scopus (1331) PubMed Crossref Google ScholarAccurso FJ Rowe SM Clancy JP Boyle MP Dunitz JM Durie PR et al.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

N Engl J Med. 2010; 363: 1991-2003View in Article Scopus (572) PubMed Crossref Google ScholarSagel SD Khan U Heltshe SL Clancy JP Borowitz D Gelfond D et al.

Clinical effectiveness of lumacaftor/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A Clinical Trial.

Ann Am Thorac Soc. 2021; 18: 75-83View in Article Scopus (4) PubMed Crossref Google ScholarShaw M Khan U Clancy JP Donaldson SH Sagel SD Rowe SM et al.

Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study.

J Cystic Fibrosis. 2020; 19: 931-933View in Article Scopus (7) PubMed Abstract Full Text Full Text PDF Google ScholarRobinson PD Latzin P Verbanck S Hall GL Horsley A Gappa M et al.

Consensus statement for inert gas washout measurement using multiple- and single- breath tests.

Eur Respir J. 2013; 41: 507-522View in Article Scopus (399) PubMed Crossref Google ScholarAmerican Thoracic S

European Respiratory S. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide.

Am J Respir Crit Care Med. 2005; 171 (2005): 912-930View in Article Scopus (2416) PubMed Crossref Google ScholarBennett WD Laube BL Corcoran T Zeman K Sharpless G Thomas K et al.

Multisite comparison of mucociliary and cough clearance measures using standardized methods.

J Aerosol Med Pulmon Drug Deliv. 2013; 26: 157-164View in Article Scopus (35) PubMed Crossref Google ScholarRowe SM Heltshe SL Gonska T Donaldson SH Borowitz D Gelfond D et al.

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Am J Respir Crit Care Med. 2014; 190: 175-184View in Article Scopus (274) PubMed Crossref Google ScholarDonaldson SH Laube BL Corcoran TE Bhambhvani P Zeman K Ceppe A et al.

Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.

JCI Insight. 2018; 3View in Article Scopus (18) PubMed Crossref Google ScholarVan Goor F Hadida S Grootenhuis PD Burton B Cao D Neuberger T et al.

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.

Proc Natl Acad Sci U S A. 2009; 106: 18825-18830View in Article Scopus (782) PubMed Crossref Google ScholarBirket SE Chu KK Houser GH Liu L Fernandez CM Solomon GM et al.

Combination therapy with cystic fibrosis transmembrane conductance regulator modulators augment the airway functional microanatomy.

Am J Physiol Lung Cell Mol Physiol. 2016; 310: L928-L939View in Article Scopus (37) PubMed Crossref Google ScholarGraeber SY Hug MJ Sommerburg O Hirtz S Hentschel J Heinzmann A et al.

Intestinal current measurements detect activation of mutant CFTR in patients with cystic fibrosis with the G551D mutation treated with ivacaftor.

Am J Respir Crit Care Med. 2015; 192: 1252-1255View in Article Scopus (34) PubMed Crossref Google ScholarRowe SM Liu B Hill A Hathorne H Cohen M Beamer JR et al.

Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutation.

PloS one. 2013; 8: e66955View in Article Scopus (39) PubMed Crossref Google ScholarGraeber SY Dopfer C Naehrlich L Gyulumyan L Scheuermann H Hirtz S et al.

Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in Phe508del homozygous patients with cystic fibrosis.

Am J Respir Crit Care Med. 2018; 197: 1433-1442View in Article Scopus (47) PubMed Crossref Google ScholarVan Goor F Hadida S Grootenhuis PD Burton B Stack JH Straley KS et al.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.

Proc Natl Acad Sci U S A. 2011; 108: 18843-18848View in Article Scopus (689) PubMed Crossref Google ScholarBurgel PR Durieu I Chiron R Mely L Prevotat A Murris-Espin M et al.

Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function.

J Cyst Fibros. 2020; View in Article Google ScholarTong K Barker D France M Burr L Greville H Visser S et al.

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.

J Cyst Fibros. 2020; 19: 415-420View in Article Scopus (5) PubMed Abstract Full Text Full Text PDF Google ScholarMcColley SA Konstan MW Ramsey BW Stuart Elborn J Boyle MP Wainwright CE et al.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

J Cyst Fibros. 2019; 18: 94-101View in Article Scopus (17) PubMed Abstract Full Text Full Text PDF Google Scholar